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Alpha-1 antitrypsin deficiency
á-1 antitrypsin is synthesised in the liver and protects lung
alveolar tissues from destruction by neutrophil elastase.1
á-1 antitrypsin deficiency is a common autosomal recessive
condition (1:1600 to 1:1800) in which liver disease results
from retention of abnormal polymerised á-1 antitrypsin in
the endoplasmic reticulum of hepatocytes, and emphysema
results from alveolar wall damage. The clinical conse-
quences of á-1 antitrypsin deficiency in childhood are
haemorrhagic disease in infancy, cholestasis in infancy, or
chronic liver disease. Lung disease attributable to á-1 anti-
trypsin deficiency does not occur in childhood, but is
closely linked to smoking in adults. Membranoproliferative
glomerulonephritis, panniculitis, and necrotising vasculitis
are associations with á-1 antitrypsin deficiency in adult
life.2–4 Diagnostic methods are summarised in table 1.
Phenotypes
á-1 antitrypsin is a protease inhibitor, and common Pi
variants have been named by their electrophoretic mobility.
PiM, of which there are several minor variants, is the nor-
mal protein. PiZ, the mutant responsible for more than
95% of cases of pulmonary and hepatic disease associated
with á-1 antititrypsin deficiency, is most frequent in Scan-
dinavia and progressively less common as one travels south
in Europe. PiS, by contrast, is most common in the Iberian
peninsula.5
Emphysema is associated both with null mutations (no
protein produced) and with mutations producing defective
or non-exported protein. Liver disease is associated only
with those mutations that produce a peptide which forms
loop sheet polymers that are retained in the liver, namely
homozygotes for PiZ, PiM (Malton), and the compound
heterozygotes PiZ−, PiSZ, and PiZI.6 The nomenclature of
genetic variants is slightly confusing: presumed homo-
zygous abnormalities such as PiZZ are conventionally
referred to as PiZ unless the null gene has been excluded
from the phenotype; thus PiZ might actually be PiZ− (Z
plus null), or PiZZ. The infant with á-1 antitrypsin
deficiency is considered to be PiZZ if both parents carry
the Z allele; this may be confirmed by genotype.
Molecular pathology
There are several recent reviews of the molecular pathology
of á-1 antitrypsin deficiency.7–9 Newly formed á-1 anti-
trypsin peptide enters the endoplasmic reticulum, where a
series of molecular chaperones superintends an orderly
process of glycosylation, disulphide bridge formation, and
folding. Having achieved its tertiary structure, á-1
antitrypsin leaves the endoplasmic reticulum and travels by
Golgi and secretory vesicles to the plasma membrane,
where it is secreted as a 55 kDa glycoprotein at a rate of
approximately 34 mg/kg/day. Newly synthesised á-1 anti-
trypsin is subject to a quality control process—protein that
fails to achieve the correct tertiary structure enters a
degradative pathway in which misfolded á-1 antitrypsin
remains bound to calnexin in the endoplasmic reticulum,
induces conjugation with ubiquitin, and leaves the
endoplasmic reticulum to be degraded in proteasomes.
The mutant peptide found in á-1 antitrypsin deficiency
of the common PiZZ phenotype (á-1 antitrypsin Z,
AAT-Z) diVers from á-1 antitrypsin M (AAT-M) only in a
single amino acid change, gly 342 → lys. The eVect of this
is a severe reduction in the rate at which the peptide folds.10
Slow folding allows peptide monomers to come together by
a loop sheet insertion mechanism to form an AAT-Z poly-
mer which is retained within the endoplasmic reticulum.12
In liver biopsies from patients with á-1 antitrypsin
deficiency, polymerised AAT-Z may be demonstrated in
the endoplasmic reticulum by electron microscopy and is
apparent histochemically as characteristic PAS positive,
diastase resistant globules.
There are many genetic disorders in which a mutated
peptide fails to achieve correct conformation and is
retained in the endoplasmic reticulum. As with AAT-Z, the
mutated protein may be functionally active but disease
results from failure of traYcking to its correct location,
whether that be the plasma membrane (for example, cystic
fibrosis or sucrase-isomaltase deficiency), other organelle
membranes (Wilson’s disease), or the extracellular fluid
(fibrinogen, protein C, or thyroglobulin deficiency).7 8
Why is it that á-1 antitrypsin deficiency diVers from all
these disorders in that the retained mutant peptide
damages the liver cell? It might simply be that á-1
antitrypsin is synthesised in large amounts, but probably
more important is the fact that polymerised AAT-Z resists
degradation. It may fancifully be imagined as doing to the
endoplasmic reticulum what haemoglobin S does to the
erythrocyte in sickle cell anaemia.
Why then do only 10% of PiZZ infants develop liver dis-
ease? Among the suggested acquired contributory factors
are the following:
Table 1 Diagnostic methods for identification of á-1 antitrypsin deficiency
Method Comment Limitations of method
Serum level Normal 0.8 to 1.8 g/l (5th and 95th centiles at 6 months).
In PiZZ, serum level usually <0.6 g/l
AATD an acute phase reactant
Liver inflammation may raise serum level in AATD.
Therefore always request phenotype
Protease inhibitor (Pi) phenotype Assessed by isoelectric focusing on polyacylamide gels.
Normal = PiMM; common AATD = PiZZ
Experienced lab essential; CMV infection may
cause a spurious Z band
Sometimes PiZZ may spuriously appear like PiSZ
in children with liver disease49
Genotype (149) Primers available for M, Z, and S alleles Only available in reference laboratories
Histochemistry PAS positive diastase resistant granules in hepatocytes Only obvious after 3 months of age
AATD, á-1 antitrypsin deficiency.
Arch Dis Child 2001;85:2–52
www.archdischild.com
 on 7 July 2005 adc.bmjjournals.comDownloaded from 
+ intrauterine infection, because PiZ babies with liver
disease tend to have been small for gestational age;
+ gut derived proteases, suggesting that breast feeding might
be protective;
+ autoimmunity, but liver directed antibodies are likely to
be secondary to liver damage rather than primary;
+ fever, because a raised temperature increases both the
production and the polymerisation rate of á-1 anti-
trypsin. Therefore, transient elevations of plasma
transaminases do indeed occur during infections in á-1
antitrypsin deficient children14;
+ cryptic hepatitis B or C infection,12 but this has not been
substantiated.13
None of these acquired factors seems suYcient to
explain fully the enormous variation in hepatic phenotype.
A more attractive hypothesis addresses possible genetic
diVerences in AAT-Z degradation. In transfected skin
fibroblasts from PiZZ patients who had developed liver
disease, AAT-Z was degraded less rapidly than in
fibroblasts from PiZZ individuals who had not developed
liver disease.15 This suggests that PiZZ patients who
develop liver disease have one of a number of possible
inborn errors of AAT-Z clearance. It is tempting to
extrapolate this concept to other traYcking disorders.
Epidemiology of á-1 antitrypsin deficiency liver
disease in childhood
In a classic piece of prospective epidemiology,14 16–20 Sveger
studied 200 000 infants in 1972–74, identifying 127 PiZ
infants among these and following them to the age of 18
years. Only 14 developed cholestatic jaundice in infancy.
Eight more had hepatosplenomegaly and mildly disturbed
liver function tests.
PROGNOSIS OF THE á-1 ANTITRYPSIN DEFICIENT CHILD WHO
DOES NOT DEVELOP INFANTILE CHOLESTASIS
The frequency of abnormal liver function tests in PiZZ
individuals with á-1 antitrypsin deficiency who do not
develop jaundice or hepatomegaly in infancy falls from
60% at 6 months to a plateau of approximately 15% at
12–18 years, with no clinical evidence of liver disease (table
2). Abnormal liver function tests may be transient—most
of those with abnormal liver function tests at 16 years were
normal at 18 and vice versa. There are occasional reports
of PiZZ children who developed new or worsening liver
dysfunction in childhood, often in association with other
severe illnesses: one case each of appendicitis and
pneumonia in Sveger’s series, and one of pancreatitis in
another report. These cases seem to be rare, and justify
excluding á-1 antitrypsin deficiency in the work up of
undiagnosed liver disease in childhood.
The prognosis of PiSZ infants is even better. None in
Sveger’s series developed jaundice in infancy, and the fre-
quency of abnormal liver function tests was lower through-
out childhood (table 2).
The risk of cirrhosis in adults is much more diYcult to
quantitate because the available data are derived either
from patients known to have á-1 antitrypsin deficient lung
disease or from studies of á-1 antitrypsin deficiency in
cases of cirrhosis. Thus 12% of aVected Swedish adults
identified through hospital admission had cirrhosis.21
Whether alcohol has anything to do with liver disease in á-1
antitrypsin deficiency is unknown; we are not therefore
justified in insisting on abstinence but do advise modera-
tion.
Whereas the heterozygous state, PiMZ, carries no risk in
childhood, it may be associated with liver disease in adults.
The PiMZ phenotype was found in 8% of adult transplant
candidates with chronic liver failure, including 27% of
those with cryptogenic cirrhosis, compared with 2–4% in
the general population.22 Inverting that statistic, however,
shows that the risk of liver disease in a particular PiMZ
individual must be small.
PROGNOSIS OF THE á-1 ANTITRYPSIN DEFICIENT CHILD WHO
DOES DEVELOP INFANTILE CHOLESTASIS
Of the 22 clinically aVected Swedish babies with á-1 anti-
trypsin deficiency, two died of cirrhosis at around 7 years,
while one died of aplastic anaemia and had cirrhosis at
necropsy.14 16–20 Of 74 children referred to King’s College
Hospital and followed to 17 years, 20 died, 20 had cirrho-
sis, 19 had persistently abnormal liver function tests, and
only 15 made a complete recovery.23 However, these were
patients whose infantile cholestasis was suYciently severe
for tertiary referral.
A more recent review24 has shown, perhaps unsurpris-
ingly, that those children who progressed to end stage liver
disease had more severe abnormalities in infancy. They
were more likely to have remained jaundiced for more than
6 weeks, to have had higher aspartate aminotransferase at
presentation, and to have had more severe changes on the
initial biopsy (comprising severe bile duct reduplication,
severe fibrosis with bridging septa, and established cirrho-
sis). Nevertheless, one should be cautious about the
outlook in an individual jaundiced infant with á-1
antitrypsin deficiency. Volpert et al point out that among
aVected children with established liver disease in whom
transplant was not immediately indicated is a group that
remains clinically stable for a prolonged period after the
presence of cirrhosis or portal hypertension is established.13
These are not initially distinguishable from those children
whose liver function declines more rapidly.
Three diagnostic points in the cholestatic infant merit
emphasis. First, the early liver biopsy appearances, with
prominent portal tract changes and with PAS positive, dia-
stase negative granules not yet apparent, may mimic those
of biliary atresia. Giant cell transformation of hepatocytes
is uncommon in á-1 antitrypsin deficiency. Second, the
plasma concentration of á-1 antitrypsin in a deficient
patient may be raised as an acute phase reactant, so the á-1
antitrypsin phenotype must be obtained. Third, determin-
ing the á-1 antitrypsin phenotype may be the most time
consuming laboratory investigation, so must (like the
coagulation screen) be requested promptly.
The indications for liver transplantation are the same as
for other hepatic disorders. After biliary atresia, á-1 anti-
trypsin deficiency is the most frequent reason for liver
transplantation in childhood. The lung does not appear to
pose any particular problem, and the perioperative and
postoperative care does not diVer from the usual routines.
Outcomes are good.25 26 Orthotopic liver transplantation
from a donor parent has been successfully performed.27
After transplant the recipient manifests the phenotype of
the donor and is expected not to be at risk of emphysema.
What is the risk of severe liver disease in the subsequent
PiZ sibling of a severely aVected proband? Psacharopoulos
et al reported that the risk was 78%,23 while others have
reported less pessimistic figures. Parents who have had a
Table 2 Frequency (%) of abnormality of alanine transaminase and/or ã
glutamate transferase in prospectively identified Swedish á-1 antitrypsin
deficient children who did not develop infantile cholestasis or hepatomegaly
Age PiZZ PiSZ
3 months 52 24
6 months 60 5
4 years 41 2
8 years 36 2
12 years 15 2
16 years 17 8
18 years 12 15
No clinical features of liver disease found at any age group.4 16–20
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severely aVected child are more likely to opt for
termination of a subsequent PiZ fetus, so it may be diYcult
to acquire further data to refine this risk.
Late haemorrhagic disease in infancy
Whereas early neonatal haemorrhagic disease in breast fed
infants is prevented by oral vitamin K at birth, cases of late
vitamin K dependent bleeding continue to occur, usually in
babies with undiagnosed cholestasis, of which á-1
antitrypsin deficiency and biliary atresia are the most com-
mon. Of 182 000 babies in the United Kingdom North
East region given 1 mg of oral vitamin K at birth and, for
the breast fed babies, recommended to receive three
further 1 mg doses at fortnightly intervals, four developed
late haemorrhagic disease.28 Two of these had not received
vitamin K and two had á-1 antitrypsin deficiency. Given
that the breast feeding rate was approximately 30% (Wari-
yar U, personal communication) and the incidence of á-1
antitrypsin deficiency is approximately 1:1800, it seems
that haemorrhagic disease occurred in 2/30 breast fed
infants with á-1 antitrypsin deficiency.
Of 332 686 Swedish babies, about 80% of whom
received 1 mg or 2 mg of oral vitamin K at birth, and
among whom breast feeding rates were reportedly high, 17
developed late haemorrhagic disease.29 Fifteen of these had
cholestatic liver disease, comprising three with á-1
antitrypsin deficiency, five with biliary atresia, and seven
with other conditions. Thus 1/35 á-1 antitrypsin deficient
infants bled. á-1 Antitrypsin deficiency was also responsi-
ble for cases of late haemorrhagic disease in other
reports.30 31 This tragic consequence of á-1 antitrypsin
deficiency and other infantile cholestases is prevented by
the more physiological Dutch protocol of giving breast fed
babies 1 mg of vitamin K at birth and 25 µg daily from
2–13 weeks of life, though late haemorrhagic disease may
still occur because of failure of compliance.32
Despite the liver disease, the grossly prolonged pro-
thrombin time dramatically improves within hours of
giving parenteral vitamin K.
Subsequent aVected siblings of an á-1 antitrypsin
deficient proband should always receive intramuscular
vitamin K at birth.
Lung disease in á-1 antitrypsin deficiency
The damage wrought by uninhibited neutrophil elastase in
the lung takes many years to manifest itself clinically.33 The
characteristic pathology seen in á-1 antitrypsin deficiency
is emphysema, caused by loss of elastic recoil. Children and
adolescents with á-1 antitrypsin deficiency have not been
shown to have significant lung function abnormalities.34 35
Although a study of aVected children with liver disease
suggested a tendency to hyperinflation,36 this was not
found in Sveger’s subsequent study of 150 adolescents.34
After the age of 30–35 years there is an accelerated decline
in forced expiratory volume in one second (FEV1), which is
considerably worsened by cigarette smoking. In a non-
smoker, symptoms are generally seen at around 50 years of
age, while smokers will be symptomatic by 30–40 years.
Although life expectancy is more diYcult to estimate with
accuracy, a combination of three studies gives a mean age
of death of 50 years in smokers, compared with 66 years in
non-smokers.37–39 Interestingly, only 3% of adolescents with
á-1 antitrypsin deficiency smoked in Sveger’s study,34 sug-
gesting that health education may be eVective in this group
of children.
Paediatricians tend to include an á-1 antitrypsin pheno-
type in the panel of tests for unexplained pulmonary
symptoms. There is little evidence in support of this,
although it is theoretically possible that a coexisting
inflammatory disease might be worsened by á-1 antitrypsin
deficiency, even in childhood. In a study of adults with
bronchiectasis there was no increase in the prevalence of
á-1 antitrypsin deficiency alleles, but more emphysema if
both diseases coexisted.40 If á-1 antitrypsin deficiency is
found in a child with lung symptoms it should not therefore
be accepted as the underlying cause of the problem, but it
might be an exacerbating factor in disease progression.
Prospects for pharmacological treatment of á-1
antitrypsin deficiency
A logical therapeutic ambition is to devise a way of moving
AAT-Z from the endoplasmic reticulum of the liver, where
it causes damage, to the plasma, where its antiprotease
activity—though less than the wild type AAT-M—would
benefit the lung. This might be achieved either by inhibit-
ing the polymerisation of AAT-Z41 or by chaperoning the
misfolded AAT-Z from endoplasmic reticulum to the
secretory pathway.2 The latter concept is common to all the
endoplasmic reticulum retention diseases. Unlike cystic
fibrosis ÄF508, incubation of cells at lower temperature
does not improve the secretory defect in á-1 antitrypsin
deficiency, but there are promising results from chemical
chaperones. In cultured mouse hepatocytes or transfected
skin fibroblasts, glycerol and 4-phenylbutyric acid achieved
increases of secretion of AAT-Z, from 3% in controls to
25% and 17%, respectively. 4-Phenylbutyric acid also
achieved increased plasma levels, reaching 20–50% of the
levels present in PiM mice with transgenic á-1 antitrypsin
deficiency.42 Sodium phenylbutyrate is already in clinical
use in urea cycle defects and is a potential form of
treatment. Its mode of action, however, remains to be
defined. Both the protein translation inhibitor cyclohex-
imide and the specific inhibitor of proteasome function,
lactacystin, prevented intracellular degradation of AAT-Z
and partially restored its vesicular transport in transfected
CHO cells and human alveolar macrophages.43 In other cell
culture work, glucosidase and mannosidase inhibitors also
achieved increased secretion.44
Augmentation therapy with á-1 antitrypsin given
intravenously has been shown to restore serum and sputum
antiprotease levels. Obviously this will be of no benefit to
infants with liver disease, but oVers the prospect of preven-
tion or treatment of lung disease. In non-randomised
observational studies, intravenous augmentation therapy
has been asociated with slower declines in FEV1
4 and
improved survival, but as yet there is no evidence of long
term benefit from a randomised controlled trial. If benefits
are seen, they appear to be confined to a subgroup of
patients with FEV1 below 65% of predicted. The one small
randomised trial which compared 28 treated patients and
28 controls showed marginal benefits in the appearances
on computed tomography, but no significant diVerences in
lung function after three years of treatment.46 The
treatment is not currently licensed in the United Kingdom.
Recombinant á-1 antitrypsin is now becoming available,
and trials of its administration by nebuliser are planned.
However, the child with á-1 antitrypsin deficiency may
never develop significant lung disease if other damaging
factors are avoided, and replacement therapy (where avail-
able) is currently only advised for significant or rapidly
progressive emphysema rather than as pre-emptive treat-
ment.
There are promising early results with gene therapy. A
normal á-1 antitrypsin gene in a plasmid–cationic
liposome complex was delivered to one nostril of each of
five aVected patients. á-1 Antitrypsin protein increased,
and interleukin 8 (as a marker of inflammation) decreased,
in nasal lavage fluid, with a peak eVect on day 5.47 While it
is technically possible to insert the AAT-M gene in an
4 Leading article
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AAT-Z mouse liver,48 that clearly will not correct the cellu-
lar defect.
Conclusions
Late haemorrhagic disease remains a hazard for breast fed
á-1 antitrypsin deficient babies with the current vitamin K
administration protocol. Continued vigilance is necessary
if cholestasis in infancy is to be promptly detected. We have
good evidence about the hepatic prognosis of á-1
antitrypsin deficiency, and recent knowledge of the
molecular pathology provides hope for newer therapeutic
approaches to this and other endoplasmic reticulum reten-
tion disorders. The indications for, and outcomes of, liver
transplantation have been delineated.
What advice should we give to young people with á-1
antitrypsin deficiency? The core message has not changed
since it was baldly stated by Janus et al in 198539: “If they
smoke, they will develop crippling emphysema by middle
age; if they do not smoke, they have a reasonable likelihood
of a full life span.” Until a simple and safe treatment is
available, this remains the only way to ensure respiratory
health in á-1 antitrypsin deficiency.
R A PRIMHAK
M S TANNER
Institute of Child Health, University of SheYeld, SheYeld Children’s
Hospital,Western Bank, SheYeld S10 2TH,UK
Correspondence to: Dr Primhak
email: r.a.primhak@sheYeld.ac.uk
Accepted 8 March 2001
1 Parmar JS, Lomas DA. Alpha-1-antitrypsin deficiency, the serpinopathies
and conformational disease. J R Coll Physicians Lond 2000;34:295–300.
2 Elzouki AN, Lindgren S, Nilsson S, et al. Severe alpha1-antitrypsin
deficiency (PiZ homozygosity) with membranoproliferative glomerulone-
phritis and nephrotic syndrome, reversible after orthotopic liver transplan-
tation. J Hepatol 1997;26:1403–7.
3 O’Riordan K, Blei A, Rao MS, et al. Alpha 1-antitrypsin deficiency-
associated panniculitis: resolution with intravenous alpha 1-antitrypsin
administration and liver transplantation. Transplantation 1997;63:480–2.
4 Mazodier P, Elzouki AN, Segelmark M, et al. Systemic necrotizing
vasculitides in severe alpha1-antitrypsin deficiency. Q J Med 1996;89:599–
611.
5 Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical dis-
tribution of Pi types S and Z. Respir Med 1998 Mar;92:367–77.
6 Mahadeva R, Chang WS, DaVorn TR, et al. Heteropolymerization of S, I,
and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999;103:999–
1006.
7 Kuznetsov G, Nigam SK. Folding of secretory and membrane proteins. N
Engl J Med 1998;339:1688–95.
8 Marcus N, Teckman JH, Perlmutter DH. Alpha1-antitrypsin deficiency:
from genotype to childhood disease. J Pediatr Gastroenterol Nutr
1998;27:65–74.
9 Bross P, Corydon TJ, Andresen BS, et al. Protein misfolding and
degradation in genetic diseases. Hum Mutat 1999;14:186–98.
10 DaVorn TR, Mahadeva R, Elliott PR, et al. A kinetic mechanism for the
polymerization of alpha1-antitrypsin. J Biol Chem 1999;274:9548–55.
11 Sivasothy P, DaVorn TR, Gettins PG, et al. Pathogenic á1-antitrypsin poly-
mers are formed by a reactive loop-{beta}-sheet A linkage. J Biol Chem
2000;275:33663–8.
12 Propst T, Propst A, Dietze O, et al. High prevalence of viral infection in
adults with homozygous and heterozygous alpha 1-antitrypsin deficiency
and chronic liver disease. Ann Intern Med 1992;117:641–5.
13 Volpert D, Molleston JP, Perlmutter DH. Alpha1-antitrypsin deficiency-
associated liver disease progresses slowly in some children. J Pediatr Gastro-
enterol Nutr 2000;31:258–63.
14 Sveger T. Prospective study of children with alpha 1-antitrypsin deficiency:
eight-year-old follow-up. J Pediatr 1984;104:91–4.
15 Wu Y, Whitman I, Molmenti E, et al. A lag in intracellular degradation of
mutant alpha 1-antitrypsin correlates with the liver disease phenotype in
homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci USA
1994;91:9014–18.
16 Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screen-
ing of 200,000 infants. N Engl J Med 1976;294:1316–21.
17 Sveger T. Alpha 1-antitrypsin deficiency in early childhood. Pediatrics 1978;
62:22–5.
18 Sveger T, Thelin T. Four-year-old children with alpha 1-antitrypsin
deficiency. Clinical follow-up and parental attitudes towards neonatal
screening. Acta Paediatr Scand 1981;70:171–7.
19 Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient
children. Acta Paediatr Scand 1988;77:847–51.
20 Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin defi-
ciency. Hepatology 1995;22:514–17.
21 Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin
deficiency, PiZ. Acta Med Scand 1978;204:345–51.
22 Graziadei IW, Joseph JJ, Wiesner RH, et al. Increased risk of chronic liver
failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatol-
ogy 1998;28:1058–63.
23 Psacharopoulos HT, Mowat AP, Cook PJ, et al. Outcome of liver disease
associated with alpha 1 antitrypsin deficiency (PiZ). Implications for
genetic counselling and antenatal diagnosis. Arch Dis Child 1983;58:882–7.
24 Francavilla R, Castellaneta SP, Hadzic N, et al. Prognosis of alpha-1-
antitrypsin deficiency-related liver disease in the era of paediatric liver
transplantion. J Hepatol 2000;32:986–92.
25 Nemeth A. Liver transplantation in alpha(1)-antitrypsin deficiency. Eur J
Pediatr 1999;158(suppl 2):S85–8.
26 Prachalias AA, Kalife M, Francavilla R, et al. Liver transplantation for
alpha-1-antitrypsin deficiency in children. Transpl Int 2000;13:207–10.
27 Colombani PM, Lau H, Prabhakaran K, et al. Cumulative experience with
pediatric living related liver transplantation. J Pediatr Surg 2000;35:9–12.
28 Wariyar U, Hilton S, Pagan J, et al. Six years’ experience of prophylactic oral
vitamin K. Arch Dis Child Fetal Neonatal Ed 2000;82:F64–8.
29 Ekelund H. Late haemorrhagic disease in Sweden 1987–89. Acta Paediatr
Scand 1991;80:966–8.
30 McNinch AW, Tripp JH. Haemorrhagic disease of the newborn in the Brit-
ish Isles: two year prospective study. BMJ 1991;303:1105–9.
31 von Kries R, Göbel U. Vitamin K prophylaxis and vitamin K deficiency
bleeding (VKDB) in early infancy. Acta Paediatr 1992;81:655–7.
32 Cornelissen M, von Kries R, Loughnan P, et al. Prevention of vitamin K
deficiency bleeding: eYcacy of diVerent multiple oral dose schedules of
vitamin K. Eur J Pediatr 1997;156:126–30.
33 Brantly M, Paul L, Miller B, et al. Clinical features and history of the
destructive lung disease associated with alpha1 antitrypsin deficiency of
adults with pulmonary symptoms. Am Rev Respir Dis 1988;138:327–36.
34 Sveger T, Piitulainen E, Arborelius MJ. Lung function in adolescents with
alpha1-antitrypsin deficiency. Acta Paediatr 1994;83:1170–3.
35 Wall M, MoeE, Eisenberg J, et al. Long-term follow-up of a cohort of chil-
dren with alpha-1-antitrypsin deficiency. J Pediatr 1990;116:248–51.
36 Hird MF, Greenough A, Mieli-Vergani G, et al. Hyperinflation in children
with liver disease due to alpha-1-antitrypsin deficiency. Pediatr Pulmonol
2000;11:212–16.
37 Black L, Kueppers F. Alpha1 antitrypsin deficiency in nonsmokers. Am Rev
Resp Dis 1978;117:421–8.
38 Tobin M, Cook P, Hutchison D. Alpha1-antitrypsin deficiency. the clinical
and physiological features of subjects homozygous for Pi type Z. Br J Dis
Chest 1983;77:12–27.
39 Janus E, Phillips N, Carrell R. Smoking, lung function and á-1 antitrypsin
deficiency. Lancet 1985;i:152–4.
40 Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha(1)-antitrypsin
alleles in patients with bronchiectasis. Chest 2000;117:415–19.
41 Elliott PR, Pei XY, DaVorn TR, et al. Topography of a 2.0 A structure of
alpha1-antitrypsin reveals targets for rational drug design to prevent
conformational disease. Protein Sci 2000;9:1274–81.
42 Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate
increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a poten-
tial pharmacological strategy for prevention of liver injury and emphysema
in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000;97:1796–801.
43 Novoradovskaya N, Lee J, Yu ZX, et al. Inhibition of intracellular degrada-
tion increases secretion of a mutant form of alpha1-antitrypsin associated
with profound deficiency. J Clin Invest 1998;101:2693–701.
44 Marcus NY, Perlmutter DH. Glucosidase and mannosidase inhibitors
mediate increased secretion of mutant alpha1 antitrypsin Z. J Biol Chem
2000;275:1987–92.
45 Seersholm N, Wercker M, Barik N, et al. Does á1-antitrypsin augmentation
therapy slow the annual decline in FEV1 in patients with severe
á1-antitrypsin deficiency? Eur Respir J 1997;10:2260–3.
46 Dirksen A, Dijkman J, Madsen F. A randomised clinical trial of
á1-antitrypsin augmentation therapy. Am J Resp Crit Care Med 1999;160:
1468–72.
47 Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with
a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects:
comparison with protein therapy. Hum Gene Ther 2000;11:1023–32.
48 Zhang G, Song YK, Liu D. Long-term expression of human alpha1-
antitrypsin gene in mouse liver achieved by intravenous administration of
plasmid DNA using a hydrodynamics-based procedure. Gene Ther 2000;7:
1344–9.
49 Whitehouse DB, Lovegrove JU, Mieli-Vergani G, et al. “SZ like” alpha
1-antitrypsin phenotypes in PI ZZ children with liver disease. Ann Hum
Genet 1994;58:1–7.
Leading article 5
www.archdischild.com
 on 7 July 2005 adc.bmjjournals.comDownloaded from 
